CYP2D6 genotyping in patients on psychoactive drug therapy

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 9, 2000, Pages 921-927

  Topic, Elizabeta ^a   Stefanovic, Mario ^a   Ivanisevic, Ana Maria ^a   Blazinic, Franciska ^b   Culav, Jadranka ^b   Skocilic, Zeljko ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Psychiatric Hospital Vrap e   (Croatia)

Author keywords

Antipsychotic drugs; CYP2D6; Multiplex PCR; Schizophrenia; Side effects

Indexed keywords

CLOMIPRAMINE; CLOZAPINE; DEBRISOQUINE 4 HYDROXYLASE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; PSYCHOTROPIC AGENT; THIORIDAZINE;

ADULT; AKATHISIA; ALLELE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG METABOLISM; DYSKINESIA; DYSTONIA; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MUTANT; PARKINSONISM; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0033759596     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.135     Document Type: Article

References (27)

1. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders
2. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene
3. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
4. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene
5. Pharmacogenetics in the practice of laboratory medicine
6. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction
7. Nomenclature for human CYP2D6 alleles
8. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
9. Effets indesirables medicamenteux. Etude epidemiologique dans un Service de Psychiatrie Hospitalo-Universitaire. Bilan de 5 annees
10. Movement disorders associated with the serotonin selective reuptake inhibitors
11. Multiplex PCR: Critical parameters and step-by-step protocol
12. Isolation of restrictible DNA
13. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long PCR technology
14. The genetic polymorphism of debrisoquin/sparteine metabolism-clinical aspects
15. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
16. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis
17. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
18. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism
19. Lack of association between debrisoquine 4-hydroxylase ((CYP2D6) gene polymorphism and schizophrenia
20. Nonfunctional CYP2D6 alleles and risk for neuroleptics-induced movement disorders in schizophrenic patients
21. CYP2D6 mutations and therapeutic outcome in schizophrenic patients
22. Pharmacogenetics of classical and new antipsychotic drugs
23. Human Cytochrome P450 Enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
24. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
25. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
26. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia